Spero Therapeutics, Roche deal

Infectious disease play Spero granted Roche the exclusive option to acquire Spero's lead antibiotic program, a preclinical inhibitor of an undisclosed target in a quorum-sensing pathway that Spero said "controls the virulence and persistence of Gram-negative bacteria." Roche said the initial focus of the program will be multidrug-resistant Pseudomonas aeruginosa. The pharma will provide undisclosed R&D funding and can exercise its option prior to an IND submission. If Roche exercises the option, Spero will receive an undisclosed upfront payment and be eligible for milestones. ...